NasdaqGS:RVMDBiotechs
FDA Priority Review For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD)
Revolution Medicines announced that the FDA has accepted for review its New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in previously treated metastatic pancreatic ductal adenocarcinoma, supported by the positive Phase 3 RASolute 302 trial showing improved survival, progression-free survival and quality of life versus standard chemotherapy.
The therapy’s inclusion in multiple high-priority U.S. and European regulatory programs, including the FDA...